The medication used for intravitreal injections include ranibizumab and bevacizumab (6), which are anti-VEGF, both have shown low prevalence of developing refractive errors in the future although bevacizumab-treated eyes in severe cases of ROP were linked to a higher likelihood of myopia or neurodevelopmental damage (7). Here, VEGFA is linked to retinopathy of prematurity.